Merck's revived antiplatelet vorapaxar gets positive FDA review
This article was originally published in Scrip
Executive Summary
Merck’s experimental drug vorapaxar, an antagonist of the protease-activated receptor-1, which the firm is seeking to market under the brand-name Zontivity, should be approved as an adjunctive therapy to reduce atherothrombotic events in patients with a history of myocardial infarction (MI), an FDA drug reviewer said on 13 January.